Compare Element Solutions Inc. Common Stock (ESI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Element Solutions Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Element Solutions Inc. Common Stock trades at $35.59 (market cap $9.07B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Element Solutions Inc. Common Stock is far larger — about 9.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Element Solutions Inc. Common Stock pays a 0.86% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Element Solutions Inc. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ESI | MRVI | |
|---|---|---|
Market Cap | $9.07B | $972.90M |
Volume | 3,090,738 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $49.09 | $9.00 |
52-Week Low | $22.99 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.00B | $1.08B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Element Solutions (ESI) trades at $37.20, up 2.06% today, with a neutral technical signal and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats and robust revenue growth from $2.55B in 2025 to $3.2B projected for 2026. Recent developments include the termination of the Solstice merger and focus on AI-driven demand and operational efficiencies.
ESI presents a mixed outlook with strong fundamental growth offset by valuation concerns. The stock trades at a premium P/E of 50.27 with analyst consensus target of $47.90 suggesting 28.8% upside. Key risks include inflation pressures and uneven industrial demand, while catalysts include continued AI adoption and data center expansion driving future performance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Element Solutions Inc. Common Stock
Element Solutions provides specialty chemical products and technical services. Its solutions support electronics, communications, automotive systems, industrial surface finishing, and offshore energy.
Read more on ESI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
